FindTrial
Sign In

Active Modulation of Cellular Dynamics Imaging (AMCDI) based on Full-Field Optical Coherence Tomography (FFOCT) for Prostate Cancer Detection/Diagnosis

Active Modulation of Cellular Dynamics Imaging (AMCDI) based on Full-Field Optical Coherence Tomography (FFOCT) for Prostate Cancer Detection/Diagnosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118761
Enrollment
Unknown
Registered
2026-02-10
Start date
2026-02-10
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Prostate cancer group:None
Normal prostate issue group:None

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Male aged 18 years or older; 2. Pathologically confirmed prostate cancer and able to undergo clear pathological staging and grading; 3. Signed informed consent; 4. Has not received neoadjuvant endocrine therapy.

Exclusion criteria

Exclusion criteria: 1. Those who refuse to sign the informed consent form; 2. Those who have received neoadjuvant endocrine therapy; 3. Those whose postoperative pathology cannot clearly determine the grade or stage; 4. Those deemed unsuitable to participate by the investigator for other reasons.

Design outcomes

Primary

MeasureTime frame
Cell density;cell volume (size);nuclear-to-cytoplasmic volume ratio / nuclear volume fraction;—

Secondary

MeasureTime frame
cellular heterogeneity;cellular pleomorphism / atypia;nuclear-cytoplasmic dynamic ratio;—

Countries

China

Contacts

Public ContactYao Lin

Peking University First Hospital

poparies@163.com+86 138 1034 5670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026